These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibitory effects of a new neuroprotective diltiazem analogue, T-477, on cloned brain Ca2+ channels expressed in Xenopus oocytes.
    Author: Kobayashi T, Strobeck M, Schwartz A, Mori Y.
    Journal: Eur J Pharmacol; 1997 Aug 13; 332(3):313-20. PubMed ID: 9300266.
    Abstract:
    A new neuroprotective agent T-477 ((R)-(+)-2-(4-chlorophenyl)-2,3-dihydro-4-diethylaminoacetyl-4H-1, 4-benzothiazine) and diltiazem are similar in chemical structures but they show different biological properties. To investigate the properties that differentiate T-477 from diltiazem, we examined the effects of the compounds on a cardiac L-type and brain non-L-type Ca2+ channels expressed in Xenopus oocytes. Cardiac L-type currents were inhibited by Ca2+ channel antagonists with an order of potency; PN200-110 isradipine > > diltiazem > T-477. Brain BI (class A)-, BII (class E)- and BIII (class B)-type Ca2+ channel currents were inhibited by T-477 with an IC50 of 45, 74 and 59 microM, respectively, whereas diltiazem barely inhibited the brain non-L-type channels and PN200-110 had no effect. T-477 caused a marked use- and frequency-dependent block of BI Ca2+ channel currents, as demonstrated by a cumulative increase of the block during a train of depolarizing pulses, which seemed to be due to a slow repriming of the drug-bound channels from inactivation. These results suggest that T-477 exerts neuroprotection of brain neurons from ischemic neuronal damage through its inhibitory action on brain Ca2+ channels that differentiates T-477 from cardiac L-type channel blockers such as diltiazem and PN200-110.
    [Abstract] [Full Text] [Related] [New Search]